# Lung cancer

lung cancer

class of disease| Subclass of | respiratory system cancer, lung disease, lung neoplasm, disease  |
| Has effect | death  |
| Studied by | pulmonology  |
| Health specialty | oncology, pulmonology  |
| Medical examination | radiography, computed tomography, bronchoscopy, biopsy  |
| Anatomical location | human lung  |
| Risk factor | smoking  |
| ICD-9-CM | 162.3, 162.5, 162.8, 162.4  |
| ICPC 2 ID | R84  |
| Wikimedia import URL |   |

**Lung cancer**, dem sanso call **lung carcinoma**, be a malignant tumor wey dey originate insyd de tissues of de lungs. Lung cancer be caused by genetic damage to de DNA of cells insyd de airways, often be caused by cigarette smoking anaa inhaling damaging chemicals. Damaged airway cells dey gain de ability to multiply unchecked, wey dey cause de growth of a tumor. Widout treatment, tumors dey spread thru out de lung, wey dey damage lung function. Eventually lung tumors metastasize, wey dey spread to oda parts of de body.

Early lung cancer often get no symptoms wey dem only fi detect am by medical imaging. As de cancer dey progress, chaw people dey experience nonspecific respiratory problems: coughing, shortness of breath, anaa chest pain. Oda symptoms dey depend on de location den size of de tumor. Those wey dem suspect dem get lung cancer typically dey undergo a series of imaging tests to determine de location den extent of any tumors. Definitive diagnosis of lung cancer dey require a biopsy of de suspected tumor wey be examined by a pathologist under a microscope. In addition to recognizing cancerous cells, a pathologist fi classify de tumor according to de type of cells e dey originate from. Around 15% of cases be small-cell lung cancer (SCLC), den de remaining 85% (de non-small-cell lung cancers anaa NSCLC) be adenocarcinomas, squamous-cell carcinomas, den large-cell carcinomas. After diagnosis, dem fi do further imaging and biopsies to determine de cancer ein stage based on how far na e spread.

Treatment for early stage lung cancer dey include surgery to remove de tumor, sam times be followed by radiation therapy den chemotherapy to kill any remaining cancer cells. Later stage cancer be treated plus radiation therapy den chemotherapy alongsyd drug treatments wey dey target specific cancer subtypes. Even plus treatment, around 20% of people per survive five years on from dema diagnosis. Survival rates be higher insyd those dem diagnose at an earlier stage, dem diagnose at a younger age, den insyd women compared to men.

Chaw lung cancer cases be caused by tobacco smoking. De remainder be caused by exposure to hazardous substances like asbestos den radon gas, anaa by genetic mutations wey arise by chance. Consequently, lung cancer prevention efforts dey encourage people make dem avoid hazardous chemicals den quit smoking. Quitting smoking both dey reduce one ein chance of developing lung cancer den dey improve treatment outcomes insyd those dem already diagnose plus lung cancer.

Lung cancer be de most diagnosed den deadliest cancer worldwide, plus 2.2 million cases insyd 2020 wey dey result in 1.8 million deaths. Lung cancer be rare insyd those younger dan 40; de average age at diagnosis be 70 years, den de average age at death 72. Incidence den outcomes dey vary widely across de world, wey dey depend on patterns of tobacco use. Prior to de advent of cigarette smoking insyd de 20th century, na lung cancer be a rare disease. Insyd de 1950s den 1960s, na increasing evidence link lung cancer den tobacco use, wey dey culminate in declarations by chaw large national health bodies wey dem discourage tobacco use.

### Dem cite

**Books Adler I (1912). *Primary Malignant Growths of the Lungs and Bronchi*. New York: Longmans, Green, and Company. OCLC 14783544. OL 24396062M.
* Broaddus C, Ernst JD, King TE, et al., eds. (2022). *Murray & Nadel's Textbook of Respiratory Medicine* (7th ed.). Elsevier. ISBN 978-0323655873.
	+ Balmes JR, Holm SM (2022). "Indoor and Outdoor Air Pollution". In Broaddus C, Ernst JD, King TE, et al. (eds.). *Murray & Nadel's Textbook of Respiratory Medicine* (7th ed.). Elsevier. pp. 1423–1434.
	+ Christiani DC, Amos CI (2022). "Lung Cancer: Epidemiology". In Broaddus C, Ernst JD, King TE, et al. (eds.). *Murray & Nadel's Textbook of Respiratory Medicine* (7th ed.). Elsevier. pp. 1018–1028.
	+ Massion PP, Lehman JM (2022). "Lung Cancer: Molecular Biology and Targets". In Broaddus C, Ernst JD, King TE, et al. (eds.). *Murray & Nadel's Textbook of Respiratory Medicine* (7th ed.). Elsevier. pp. 1005–1017.
	+ Pastis NJ, Gonzalez AV, Silvestri GA (2022). "Lung Cancer: Diagnosis and Staging". In Broaddus C, Ernst JD, King TE, et al. (eds.). *Murray & Nadel's Textbook of Respiratory Medicine* (7th ed.). Elsevier. pp. 1039–1051.
	+ Rivera P, Mody GN, Weiner AA (2022). "Lung Cancer: Treatment". In Broaddus C, Ernst JD, King TE, et al. (eds.). *Murray & Nadel's Textbook of Respiratory Medicine* (7 ed.). Elsevier. pp. 1052–1065.
	+ Tanoue L, Mazzone PJ, Tanner NT (2022). "Lung Cancer: Screening". In Broaddus C, Ernst JD, King TE, et al. (eds.). *Murray & Nadel's Textbook of Respiratory Medicine* (7th ed.). Elsevier. pp. 1029–1038.
* European Commission. Directorate General for Research and Innovation.; European Commission Group of Chief Scientific Advisors. (2022). *Cancer screening in the European Union*. Publications Office of the European Union. doi:10.2777/867180. ISBN 978-92-76-45603-2.
* Horn L, Iams WT (2022). "78: Neoplasms of the Lung". In Loscalzo J, Fauci A, Kasper D, et al. (eds.). *Harrison's Principles of Internal Medicine* (21st ed.). McGraw Hill. ISBN 978-1264268504.
* Morgensztern D, Boffa D, Chen A, Dhanasopon A, Goldberg SB, Decker RH, Devarakonda S, Ko JP, Solis Soto LM, Waqar SN, Wistuba II, Herbst RS (April 2023). "80: Cancer of the Lung". In Bast RC, Byrd JC, Croce CM, et al. (eds.). *Holland-Frei Cancer Medicine* (10th ed.). Wiley. ISBN 978-1-119-75068-0.
* Salahuddin M, Ost DE (2023). "110: Approach to the Patient with Pulmonary Nodules". In Grippi MA, Antin-Ozerkis DE, Dela Cruz CS, et al. (eds.). *Fishman's Pulmonary Diseases and Disorders* (6th ed.). McGraw Hill. ISBN 978-1260473988.

**Journal articles Alexander M, Kim SY, Cheng H (December 2020). "Update 2020: Management of Non-Small Cell Lung Cancer". *Lung*. **198** (6): 897–907. doi:10.1007/s00408-020-00407-5. PMC 7656891. PMID 33175991.
* Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. (March 2018). "Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries". *Lancet*. **391** (10125): 1023–1075. doi:10.1016/S0140-6736(17)33326-3. PMC 5879496. PMID 29395269.
* Aragon KN (June 2020). "Palliative Care in Lung Cancer". *Clin Chest Med*. **41** (2): 281–293. doi:10.1016/j.ccm.2020.02.005. PMID 32402363. S2CID 218633948.
* Arnott D, Lindorff K, Goddard A (August 2022). "Tobacco control: the FCTC provides the route to the finish line". *Lancet*. **400** (10350): 427. doi:10.1016/S0140-6736(22)01334-4. PMID 35878621. S2CID 250960604.
* Bade BC, Dela Cruz CS (March 2020). "Lung Cancer 2020: Epidemiology, Etiology, and Prevention". *Clin Chest Med*. **41** (1): 1–24. doi:10.1016/j.ccm.2019.10.001. PMID 32008623. S2CID 211015015.
* Batra H, Pawar S, Bahl D (February 2021). "Current clinical trials and patent update on lung cancer: a retrospective review". *Lung Cancer Management*. **10** (5) LMT45. doi:10.2217/lmt-2020-0029. PMC 8162165. PMID 34084211.
* Blum A (July 1999). "Alton ochsner, MD, 1896–1981 anti-smoking pioneer". *Ochsner J*. **1** (3): 102–105. PMC 3145444. PMID 21845126.
* Bracken-Clarke D, Kapoor D, Baird AM, Buchanan PJ, Gately K, Cuffe S, Finn SP (March 2021). "Vaping and lung cancer – A review of current data and recommendations". *Lung Cancer*. **153**: 11–20. doi:10.1016/j.lungcan.2020.12.030. PMID 33429159. S2CID 231586192.
* Brandt AM (January 2012). "Inventing conflicts of interest: a history of tobacco industry tactics". *Am J Public Health*. **102** (1): 63–71. doi:10.2105/AJPH.2011.300292. PMC 3490543. PMID 22095331.
* Canadian Task Force on Preventive Health Care (April 2016). "Recommendations on screening for lung cancer". *CMAJ*. **188** (6): 425–432. doi:10.1503/cmaj.151421. ISSN 0820-3946. PMC 4818132. PMID 26952527.
* Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. (January 2016). "The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (8th) ed. of the TNM Classification for Lung Cancer". *J Thorac Oncol*. **11** (1): 39–51. doi:10.1016/j.jtho.2015.09.009. hdl:10044/1/31538. PMID 26762738. S2CID 5368645.
* Hall W (December 2022). "The 1964 US Surgeon General's report on smoking and health". *Addiction*. **117** (12): 3170–3175. doi:10.1111/add.16007. PMID 35852022. S2CID 250642397.
* Horn L, Johnson DH (July 2008). "Evarts A. Graham and the first pneumonectomy for lung cancer". *Journal of Clinical Oncology*. **26** (19): 3268–3275. doi:10.1200/JCO.2008.16.8260. PMID 18591561. Archived from the original on 17 March 2020. Retrieved 20 March 2009.
* Jassem J (May 2019). "Tobacco smoking after diagnosis of cancer: clinical aspects". *Translational Lung Cancer Research*. **8** (Suppl 1): S50 – S58. doi:10.21037/tlcr.2019.04.01. PMC 6546630. PMID 31211105.
* Jonas DE, Reuland DS, Reddy SM, Nagle M, Clark SD, Weber RP, Enyioha C, Malo TL, Brenner AT, Armstrong C, Coker-Schwimmer M, Middleton JC, Voisin C, Harris RP (March 2021). "Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force". *JAMA*. **325** (10): 971–987. doi:10.1001/jama.2021.0377. PMID 33687468. S2CID 232159404.
* Jones KD (December 2013). "Whence lepidic?: the history of a Canadian neologism". *Arch Pathol Lab Med*. **137** (12): 1822–1824. doi:10.5858/arpa.2013-0144-HP. PMID 23937575.
* Kamath SD, Kircher SM, Benson AB (July 2019). "Comparison of Cancer Burden and Nonprofit Organization Funding Reveals Disparities in Funding Across Cancer Types". *J Natl Compr Canc Netw*. **17** (7): 849–854. doi:10.6004/jnccn.2018.7280. PMID 31319386. S2CID 197666475.
* Lim RB (October 2016). "End-of-life care in patients with advanced lung cancer". *Ther Adv Respir Dis*. **10** (5): 455–467. doi:10.1177/1753465816660925. PMC 5933619. PMID 27585597.